Tests efimosfermin alfa in people with cirrhosis caused by fatty liver disease
Tests efimosfermin alfa against placebo in adults with early cirrhosis from MASH.
Plain-language title generated from the registry record
Registry title: A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Key facts
- Where
- Austin, Baltimore, Chandler, Dallas, Fayetteville, Fresno, Georgetown, Houston, Kansas City, Lancaster, Marietta, Mesa, Miami, New York, Pasadena, Pearland, Rialto, Richmond, San Antonio, Santa Maria, Tucson, Viera, Waco, and Wilson, United StatesSee the 24 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06920043, who can take part
Where in United States
- AustinAustin, United StatesTaking people
- BaltimoreBaltimore, United StatesTaking people
- ChandlerChandler, United StatesTaking people
- DallasDallas, United StatesTaking people
- FayettevilleFayetteville, United StatesTaking people
- FresnoFresno, United StatesTaking people
- GeorgetownGeorgetown, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Kansas CityKansas City, United StatesTaking people
- LancasterLancaster, United StatesTaking people
- MariettaMarietta, United StatesTaking people
- MesaMesa, United StatesTaking people
- MiamiMiami, United StatesTaking people
- New YorkNew York, United StatesTaking people
- PasadenaPasadena, United StatesTaking people
- PearlandPearland, United StatesTaking people
- RialtoRialto, United StatesTaking people
- RichmondRichmond, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- Santa MariaSanta Maria, United StatesTaking people
- TucsonTucson, United StatesTaking people
- VieraViera, United StatesTaking people
- WacoWaco, United StatesTaking people
- WilsonWilson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GlaxoSmithKline
- Trial code
- NCT06920043
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.Read full original descriptionShow less
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Inclusion: Ability to understand and sign a written informed consent form (ICF); Age 18 through 75 years at enrollment; History or presence of 2 or more of the 5 components of metabolic syndrome; Liver biopsy confirmation of MASH consistent with stage F4 fibrosis; Other inclusion criteria may apply.
Exclusion: Individuals with chronic liver disease from other causes, or any history or evidence of decompensated liver disease; History of type 1 diabetes; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × the upper limit of normal (ULN); Other exclusion criteria may apply.